According to Zacks, “DelMar Pharmaceuticals, Inc. is involved in developing drug for orphan cancer indications. DelMar Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
A number of other research analysts have also weighed in on DMPI. ValuEngine lowered shares of DelMar Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 2nd. Maxim Group began coverage on shares of DelMar Pharmaceuticals in a research report on Friday, September 6th. They set a buy rating for the company. Finally, Dawson James reissued a buy rating on shares of DelMar Pharmaceuticals in a research report on Thursday, July 11th.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
Further Reading: How does a security become overbought?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.